机译:多发性骨髓瘤的抗B细胞成熟抗原双特异性抗体
California Institute for Biomedical Research, 11119 North Torrey Pines Road, Suite 100, La Jolla, California 92037, United States;
California Institute for Biomedical Research, 11119 North Torrey Pines Road, Suite 100, La Jolla, California 92037, United States;
Department of Chemistry and the Skaggs Institute for Chemical Biology The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States;
California Institute for Biomedical Research, 11119 North Torrey Pines Road, Suite 100, La Jolla, California 92037, United States;
California Institute for Biomedical Research, 11119 North Torrey Pines Road, Suite 100, La Jolla, California 92037, United States;
California Institute for Biomedical Research, 11119 North Torrey Pines Road, Suite 100, La Jolla, California 92037, United States;
Department of Immunology and Microbial Science, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States;
California Institute for Biomedical Research, 11119 North Torrey Pines Road, Suite 100, La Jolla, California 92037, United States;
机译:用AMG 420处理,一种抗B细胞成熟抗原(BCMA)双特异性T细胞参录手(咬合(R))抗体构建体,诱导最小的残留疾病(MRD)在复发和/或难治度(R / R) )多发性骨髓瘤(mm)患者:先进(FIH)I剂量升级研究的结果
机译:I阶段,开放标签研究,评估PF-06863135的安全性,药代动力学,药效和临床活性,B细胞成熟抗原/ CD3双特异性抗体,复发/难治性先进的多发性骨髓瘤患者
机译:AFM26的临床前表征,一种新型B细胞成熟抗原(BCMA) - 用于骨髓瘤的高亲和力retarged治疗NK细胞的高亲和力次数抗体
机译:开发一种完全人体T细胞接合双特异性抗体治疗多发性骨髓瘤
机译:用于重定向T细胞对肿瘤细胞免疫的新型抗体分子的开发:双特异性单链抗体
机译:Teclistamab是一种活性T细胞其针对多种骨髓瘤的B细胞成熟抗原的双特异性抗体
机译:belantamab治疗后继发效应:一种新的抗B细胞成熟抗原单克隆抗体对多发性骨髓瘤
机译:体外抗原特异性抗体对人外周血单个核细胞对斑疹伤寒组立克次体的物种特异性表面蛋白抗原的反应。产生抗原依赖性抑制T细胞